Shots:

• Bemcentinib has been selected as the first potential treatment to be fast-tracked under UK’s P-II ACCORD program that rapidly evaluates bemcentinib’s effectiveness in hospitalized UK NHS patients with COVID-19
• The study will commence testing of bemcentinib vs SOC in 120 patients across 6 UK NHS hospital trusts with its anticipated results within few months. If results are positive- bemcentinib will rapidly advance into the large-scale P-III studies currently in progress across the UK
• Bemcentinib (qd) is a highly selective AXL kinase inhibitor- act by blocking viral entry and enhancing the antiviral type I interferon response. The preclinical data demonstrated that it has the potential to treat early SARS-CoV-2 infection

Click here ­to­ read full press release/ article | Ref: Bergenbio | Image: Bergenbio